Published in Biochem Biophys Res Commun on September 05, 2003
The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev (2007) 6.79
Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques. Bioinformatics (2009) 3.00
Angiotensin II-dependent persistent podocyte loss from destabilized glomeruli causes progression of end stage kidney disease. Kidney Int (2011) 2.28
Chemistry and biology of multicomponent reactions. Chem Rev (2012) 2.09
Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest (2008) 1.70
Novel druggable hot spots in avian influenza neuraminidase H5N1 revealed by computational solvent mapping of a reduced and representative receptor ensemble. Chem Biol Drug Des (2008) 1.69
Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes (2008) 1.57
The catalytic mechanism of an aspartic proteinase explored with neutron and X-ray diffraction. J Am Chem Soc (2008) 1.33
New pharmacological treatments for improving renal outcomes in diabetes. Nat Rev Nephrol (2010) 1.29
Identification of rtl1, a retrotransposon-derived imprinted gene, as a novel driver of hepatocarcinogenesis. PLoS Genet (2013) 1.15
Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats. Am J Pathol (2010) 1.09
Aliskiren reduces body-weight gain, adiposity and plasma leptin during diet-induced obesity. Br J Pharmacol (2009) 1.05
Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. Br J Clin Pharmacol (2011) 0.91
The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vasc Health Risk Manag (2008) 0.90
Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors. Fibrogenesis Tissue Repair (2011) 0.87
Therapeutic approaches to slowing the progression of diabetic nephropathy - is less best? Drugs Context (2013) 0.86
Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome. J Am Soc Hypertens (2008) 0.85
Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol (2004) 0.85
Development, evaluation and application of 3D QSAR Pharmacophore model in the discovery of potential human renin inhibitors. BMC Bioinformatics (2011) 0.84
Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren. Eur J Clin Pharmacol (2010) 0.84
Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br J Clin Pharmacol (2006) 0.82
Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy. Vasc Health Risk Manag (2008) 0.82
Aliskiren attenuates steatohepatitis and increases turnover of hepatic fat in mice fed with a methionine and choline deficient diet. PLoS One (2013) 0.81
Combined aliskiren and amlodipine reduce albuminuria via reduction in renal inflammation in diabetic rats. J Cardiovasc Pharmacol (2012) 0.81
Aliskiren--an orally active renin inhibitor. Review of pharmacology, pharmacodynamics, kinetics, and clinical potential in the treatment of hypertension. Vasc Health Risk Manag (2007) 0.80
Aliskiren - an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension. Arch Med Sci (2013) 0.78
Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects. Eur J Clin Pharmacol (2011) 0.78
Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug. Am J Med (2008) 0.78
What is the role of renin inhibition during rat septic conditions: preventive effect of aliskiren on sepsis-induced lung injury. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.78
Intratubular Renin-Angiotensin System in Hypertension. Curr Hypertens Rev (2006) 0.78
Can Aliskiren be Considered as a New Novel Drug for Hypertension? Cureus (2015) 0.78
Chronic Activation of the Renin-Angiotensin System Induces Lung Fibrosis. Sci Rep (2015) 0.77
Therapeutic vaccines against human and rat renin in spontaneously hypertensive rats. PLoS One (2013) 0.77
Role of aliskiren in blood pressure control and renoprotection. Int J Nephrol Renovasc Dis (2011) 0.77
New class of agents for treatment of hypertension: focus on direct renin inhibition. Vasc Health Risk Manag (2010) 0.76
Purification and characterization of recombinant human renin for X-ray crystallization studies. BMC Biochem (2008) 0.76
Local delivery of a direct renin inhibitor into the kidney ameliorates progression of experimental glomerulonephritis. Clin Exp Nephrol (2012) 0.76
Aliskiren displays long-lasting interactions with human renin. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.76
Renin and cardiovascular disease: Worn-out path, or new direction. World J Cardiol (2011) 0.76
Discovery of MK-8718, an HIV Protease Inhibitor Containing a Novel Morpholine Aspartate Binding Group. ACS Med Chem Lett (2016) 0.75
Enantioselective synthesis of (-)-chloramphenicol via silver-catalysed asymmetric isocyanoacetate aldol reaction. Org Biomol Chem (2015) 0.75
Metal Ion Modeling Using Classical Mechanics. Chem Rev (2017) 0.75
Olmesartan attenuates tacrolimus-induced biochemical and ultrastructural changes in rat kidney tissue. Biomed Res Int (2014) 0.75
Oral renin inhibitors in clinical practice: a perspective review. Ther Adv Chronic Dis (2012) 0.75
Aliskiren: An orally active renin inhibitor. J Pharm Bioallied Sci (2011) 0.75
Potential of RAS inhibition to improve metabolic bone disorders. Biomed Res Int (2013) 0.75
Optimizing combination therapy in the management of hypertension: the role of the aliskiren, amlodipine, and hydrochlorothiazide fixed combination. Integr Blood Press Control (2013) 0.75
Aliskiren in hypertension: evidence for its potential therapeutic value. Core Evid (2005) 0.75
Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension. Expert Rev Cardiovasc Ther (2012) 0.75
Renin-angiotensin system blockers regulate the metabolism of isolated fat cells in vitro. Braz J Med Biol Res (2016) 0.75
Tailored Assays for Pharmacokinetic and Pharmacodynamic Investigations of Aliskiren and Enalapril in Children: An Application in Serum, Urine, and Saliva. J Pediatr Pharmacol Ther (2016) 0.75
Renin Inhibition with Aliskiren: A Decade of Clinical Experience. J Clin Med (2017) 0.75
Renin Angiotensin Aldosterone Inhibition in the Treatment of Cardiovascular Disease. Pharmacol Res (2017) 0.75
Renin inhibitor aliskiren exerts beneficial effect on trabecular bone by regulating skeletal renin-angiotensin system and kallikrein-kinin system in ovariectomized mice. Osteoporos Int (2015) 0.75
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation (2006) 10.05
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet (2010) 8.39
TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature (2011) 6.29
Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet (2007) 5.21
Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension (2005) 5.05
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA (2013) 4.82
Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med (2003) 4.59
Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol (2010) 3.93
Ambulatory arterial stiffness index as a predictor of cardiovascular mortality in the Dublin Outcome Study. Hypertension (2006) 3.42
High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol (2004) 3.34
European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens (2008) 3.32
Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension (2013) 2.89
Drug export pathway of multidrug exporter AcrB revealed by DARPin inhibitors. PLoS Biol (2007) 2.89
Multicentre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types: a case-control study. Lancet Neurol (2007) 2.88
The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem (2002) 2.75
Prognostic value of reading-to-reading blood pressure variability over 24 hours in 8938 subjects from 11 populations. Hypertension (2010) 2.64
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care (2005) 2.59
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
Ambulatory blood pressure monitoring in 9357 subjects from 11 populations highlights missed opportunities for cardiovascular prevention in women. Hypertension (2011) 2.33
Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens (2010) 2.28
Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genet (2010) 2.24
Ambulatory arterial stiffness index derived from 24-hour ambulatory blood pressure monitoring. Hypertension (2006) 2.19
NMR structure of the apoptosis- and inflammation-related NALP1 pyrin domain. Structure (2003) 2.15
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am J Hum Genet (2010) 2.15
Chronic graft-versus-host-disease-like dermopathy in a child with CD4+ cell microchimerism. Dermatology (2005) 2.11
Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. Am J Hum Genet (2009) 2.04
Insights into the regulatory mechanism for caspase-8 activation. Mol Cell (2003) 2.01
mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res (2009) 2.01
Designed to be stable: crystal structure of a consensus ankyrin repeat protein. Proc Natl Acad Sci U S A (2003) 1.98
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet (2012) 1.96
Making ambulatory blood pressure monitoring accessible in pharmacies. Blood Press Monit (2014) 1.95
Inhibition of caspase-2 by a designed ankyrin repeat protein: specificity, structure, and inhibition mechanism. Structure (2007) 1.93
Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation (2005) 1.89
Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study. Circulation (2008) 1.88
Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens (2004) 1.87
Blood pressure and urinary sodium in men and women: the Norfolk Cohort of the European Prospective Investigation into Cancer (EPIC-Norfolk). Am J Clin Nutr (2004) 1.86
Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension (2006) 1.81
Self-measured versus ambulatory blood pressure in the diagnosis of hypertension. J Hypertens (2003) 1.78
Allosteric inhibition of aminoglycoside phosphotransferase by a designed ankyrin repeat protein. Structure (2005) 1.75
Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension (2002) 1.71
Crystal structure of the multidrug exporter MexB from Pseudomonas aeruginosa. J Mol Biol (2009) 1.69
Crystal structure of a heterodimeric ABC transporter in its inward-facing conformation. Nat Struct Mol Biol (2012) 1.66
Transport of drugs by the multidrug transporter AcrB involves an access and a deep binding pocket that are separated by a switch-loop. Proc Natl Acad Sci U S A (2012) 1.66
Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem (2002) 1.62
The International Database of Ambulatory Blood Pressure in relation to Cardiovascular Outcome (IDACO): protocol and research perspectives. Blood Press Monit (2007) 1.62
The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. J Hypertens (2008) 1.61
A new solar-powered blood pressure measuring device for low-resource settings. Hypertension (2010) 1.61
European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens (2014) 1.58
Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J (2006) 1.58
Blood pressure variability: clarity for clinical practice. Hypertension (2010) 1.55
LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet (2011) 1.52
Crystal structure and functional analysis of Escherichia coli glutamate decarboxylase. EMBO J (2003) 1.50
Outcome-driven thresholds for ambulatory pulse pressure in 9938 participants recruited from 11 populations. Hypertension (2013) 1.50
Impact of applying the more stringent validation criteria of the revised European Society of Hypertension International Protocol 2010 on earlier validation studies. Blood Press Monit (2011) 1.50
Risk stratification by 24-hour ambulatory blood pressure and estimated glomerular filtration rate in 5322 subjects from 11 populations. Hypertension (2012) 1.49
Determinants of the ambulatory arterial stiffness index in 7604 subjects from 6 populations. Hypertension (2008) 1.48
Responses of the ambulatory arterial stiffness index and other measures of arterial function to antihypertensive drugs. Hypertens Res (2011) 1.47
Rationale and design of the AdRem study: evaluating the effects of blood pressure lowering and intensive glucose control on vascular retinal disorders in patients with type 2 diabetes mellitus. Contemp Clin Trials (2006) 1.47
Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension (2003) 1.46
Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters. Proc Natl Acad Sci U S A (2013) 1.46
Blood pressure load does not add to ambulatory blood pressure level for cardiovascular risk stratification. Hypertension (2014) 1.44
Structural basis of chaperone-subunit complex recognition by the type 1 pilus assembly platform FimD. EMBO J (2005) 1.42
Night-time blood pressure and target organ damage: a comparative analysis of absolute blood pressure and dipping status. J Hypertens (2015) 1.41
White-coat hypertension: new insights from recent studies. Hypertension (2013) 1.39
Structure of the PRYSPRY-domain: implications for autoinflammatory diseases. FEBS Lett (2005) 1.36
Subgroup analyses on return to work in sick-listed employees with low back pain in a randomised trial comparing brief and multidisciplinary intervention. BMC Musculoskelet Disord (2011) 1.33
Structural basis and kinetics of inter- and intramolecular disulfide exchange in the redox catalyst DsbD. EMBO J (2004) 1.32
Tissue Doppler E/E' ratio is a powerful predictor of primary cardiac events in a hypertensive population: an ASCOT substudy. Eur Heart J (2009) 1.30
Computer users' risk factors for developing shoulder, elbow and back symptoms. Scand J Work Environ Health (2004) 1.29
Precision is essential for efficient catalysis in an evolved Kemp eliminase. Nature (2013) 1.28
Ambulatory arterial stiffness index and 24-hour ambulatory pulse pressure as predictors of mortality in Ohasama, Japan. Stroke (2007) 1.25
Quality control of the blood pressure phenotype in the European Project on Genes in Hypertension. Blood Press Monit (2002) 1.21
Intracellular kinase inhibitors selected from combinatorial libraries of designed ankyrin repeat proteins. J Biol Chem (2005) 1.17
Structural and biochemical studies on procaspase-8: new insights on initiator caspase activation. Structure (2009) 1.16
Oxidoreductase activity of oligosaccharyltransferase subunits Ost3p and Ost6p defines site-specific glycosylation efficiency. Proc Natl Acad Sci U S A (2009) 1.15
Self monitoring of blood pressure at home. BMJ (2004) 1.14
Chaperone-assisted crystallography with DARPins. Structure (2008) 1.14
Infinite kinetic stability against dissociation of supramolecular protein complexes through donor strand complementation. Structure (2008) 1.12
Aspartic proteases in drug discovery. Curr Pharm Des (2007) 1.12
Validation of sick leave measures: self-reported sick leave and sickness benefit data from a Danish national register compared to multiple workplace-registered sick leave spells in a Danish municipality. BMC Public Health (2012) 1.11
Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov (2008) 1.10
Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens (2005) 1.10
DsbL and DsbI form a specific dithiol oxidase system for periplasmic arylsulfate sulfotransferase in uropathogenic Escherichia coli. J Mol Biol (2008) 1.10
Vacuolar protein sorting: two different functional states of the AAA-ATPase Vps4p. J Mol Biol (2008) 1.09
Extended substrate recognition in caspase-3 revealed by high resolution X-ray structure analysis. J Mol Biol (2006) 1.08
Structural basis and kinetics of DsbD-dependent cytochrome c maturation. Structure (2005) 1.08
Ultra-broadband infrared pump-probe spectroscopy using synchrotron radiation and a tuneable pump. Rev Sci Instrum (2011) 1.08
Escherichia coli acid resistance: pH-sensing, activation by chloride and autoinhibition in GadB. EMBO J (2006) 1.07